These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 25336142)

  • 1. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.
    Matulonis UA; Oza AM; Ho TW; Ledermann JA
    Cancer; 2015 Jun; 121(11):1737-46. PubMed ID: 25336142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
    Tate Thigpen J
    Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
    Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
    Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
    Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
    Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer.
    Kawakami H; Okamoto I; Hayashi H; Taguri M; Morita S; Nakagawa K
    Eur J Cancer; 2013 Sep; 49(14):3003-9. PubMed ID: 23791540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
    Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
    JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.
    Colloca G; Venturino A
    Med Oncol; 2017 May; 34(5):87. PubMed ID: 28391579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
    Sidhu R; Rong A; Dahlberg S
    Clin Cancer Res; 2013 Mar; 19(5):969-76. PubMed ID: 23303214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of post-progression survival in lung cancer.
    Imai H; Kaira K; Minato K
    Thorac Cancer; 2017 Sep; 8(5):379-386. PubMed ID: 28627767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Tian C; Bookman MA
    Gynecol Oncol; 2010 May; 117(2):324-9. PubMed ID: 20185168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval.
    Conde-Estévez D; Tusquets I; Servitja S; Martínez-García M; Salas E; Albanell J
    Anticancer Drugs; 2014 Oct; 25(9):992-7. PubMed ID: 24892723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.
    Saad ED; Katz A; Buyse M
    J Clin Oncol; 2010 Apr; 28(11):1958-62. PubMed ID: 20194852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
    Herzog TJ; Armstrong DK; Brady MF; Coleman RL; Einstein MH; Monk BJ; Mannel RS; Thigpen JT; Umpierre SA; Villella JA; Alvarez RD
    Gynecol Oncol; 2014 Jan; 132(1):8-17. PubMed ID: 24239753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance.
    Minion LE; Coleman RL; Alvarez RD; Herzog TJ
    Gynecol Oncol; 2016 Feb; 140(2):193-8. PubMed ID: 26631607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
    Wilkerson J; Fojo T
    Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.
    Mahner S; Eulenburg C; Staehle A; Wegscheider K; Reuss A; Pujade-Lauraine E; Harter P; Ray-Coquard I; Pfisterer J; du Bois A
    Eur J Cancer; 2013 Jan; 49(1):142-9. PubMed ID: 22921185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment goals in ovarian cancer.
    Ozols RF
    Int J Gynecol Cancer; 2005; 15 Suppl 1():3-11. PubMed ID: 15839952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.